- Home
- FSM vs SDGR Comparison
FSM vs SDGR Comparison
Compare FSM & SDGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FSM
- SDGR
- Stock Information
- Founded
- FSM 1990
- SDGR 1990
- Country
- FSM Canada
- SDGR United States
- Employees
- FSM N/A
- SDGR N/A
- Industry
- FSM Precious Metals
- SDGR Biotechnology: Pharmaceutical Preparations
- Sector
- FSM Basic Materials
- SDGR Health Care
- Exchange
- FSM Nasdaq
- SDGR Nasdaq
- Market Cap
- FSM 1.5B
- SDGR 1.3B
- IPO Year
- FSM N/A
- SDGR 2020
- Fundamental
- Price
- FSM $4.67
- SDGR $18.73
- Analyst Decision
- FSM Hold
- SDGR Buy
- Analyst Count
- FSM 2
- SDGR 10
- Target Price
- FSM $5.75
- SDGR $32.90
- AVG Volume (30 Days)
- FSM 7.6M
- SDGR 910.2K
- Earning Date
- FSM 11-06-2024
- SDGR 11-12-2024
- Dividend Yield
- FSM N/A
- SDGR N/A
- EPS Growth
- FSM N/A
- SDGR N/A
- EPS
- FSM 0.08
- SDGR N/A
- Revenue
- FSM $1,025,155,000.00
- SDGR $193,348,000.00
- Revenue This Year
- FSM $23.22
- SDGR N/A
- Revenue Next Year
- FSM N/A
- SDGR $24.24
- P/E Ratio
- FSM $58.50
- SDGR N/A
- Revenue Growth
- FSM 38.19
- SDGR N/A
- 52 Week Low
- FSM $2.63
- SDGR $16.67
- 52 Week High
- FSM $6.36
- SDGR $38.00
- Technical
- Relative Strength Index (RSI)
- FSM 45.41
- SDGR 53.47
- Support Level
- FSM $4.47
- SDGR $18.42
- Resistance Level
- FSM $4.93
- SDGR $23.65
- Average True Range (ATR)
- FSM 0.22
- SDGR 1.00
- MACD
- FSM -0.04
- SDGR 0.28
- Stochastic Oscillator
- FSM 31.87
- SDGR 36.87
About FSM Fortuna Silver Mines Inc (Canada)
Fortuna Mining Corp is a Canadian-based precious metals mining company with mines in the Latin America and West Africa regions producing gold and silver. It operate mines in Argentina, Burkina Faso, Cote d'Ivoire, Mexico, and Peru.
About SDGR Schrodinger Inc.
Schrodinger Inc is a healthcare-based software company. Its operating segments are Software and Drug discovery. Through the Software segment, the company is focused on selling software to transform drug discovery across the life sciences industry and customers in materials science industries. In the Drug discovery segment, it is engaged in generating revenue from a portfolio of preclinical and clinical programs, internally and through collaborations. It generates revenue from the sales of software solutions and from research funding and milestone payments from its drug discovery collaborations.